Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.60 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 9/20 | 0.55 |
| ▸ | GLP1R | P43220 | 2/20 | 0.54 |
| ▸ | GCGR | P47871 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.53 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.53 |
| ▸ | CALCR | P30988 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33618 | 0.76 | INSR (0.75) | INSRNPY2RRXFP1 | |
| SCHEMBL14840198 | 0.76 | INSR (0.93) | INSRNPY2RRXFP1RAMP1RAMP2 | |
| SCHEMBL15669703 | 0.76 | INSR (0.95) | RXFP4RXFP3INSRNPY2RRXFP1 | |
| Anx-042 SCHEMBL29392245 | 0.75 | RAMP1 (0.59) | RXFP4RXFP3INSRNPY2RGLP1R | |
| SCHEMBL63125 | 0.75 | INSR (0.98) | RXFP4RXFP3INSRNPY2RRXFP1 | |
| SCHEMBL29363489 | 0.74 | INSR (0.63) | RXFP4RXFP3INSRNPY2RGLP1R | |
| SCHEMBL29388353 | 0.74 | RAMP1 (0.57) | RXFP4RXFP3INSRNPY2RRAMP1 | |
| SCHEMBL26952437 | 0.74 | MC4R (0.59) | INSRNPY2RGLP1RGCGRTEAD1 | |
| SCHEMBL20003971 | 0.74 | GLP1R (0.51) | NPY2RGLP1RGCGRTEAD1 | |
| SCHEMBL29358226 | 0.73 | KLK7 (0.56) | RXFP4RXFP3INSRGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | claimed |
| US-20240208933-A1 | CRYSTALLINE INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-06-27 | — | — | US | claimed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | claimed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | claimed |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-11267799-B2 | Solid forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11267801-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3960740-A1 | CRYSTALLINE FORMS OF ETHYL ((S)-((((2R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-FLUORO-2,5-DIHYDROFURAN-2-YL)OXY)METHYL)(PHENOXY)PHOSPHORYL)-L-ALANINATE (GS-9131) VANILLATE FOR TREATING VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3960735-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| EP-3955921-A1 | 2-IMINO-5-OXO-IMIDAZOLIDINE INHIBITORS OF HIV PROTEASE | GILEAD SCIENCES, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | RXFP4 175/4885RXFP3 172/4885INSR 1201/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | RXFP4 2140/4885RXFP3 837/4885INSR 3043/4885 |
| US-20240208933-A1 | CRYSTALLINE INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSS, CTRL, CPN1 | RXFP4 4444/4885RXFP3 3839/4885INSR 4020/4885 |
| US-11267801-B2 | Therapeutic compounds | NPC1, CCR5, FURIN | RXFP4 4718/4885RXFP3 4519/4885INSR 1956/4885 |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | CHKA, SLC5A7, SLC44A1 | RXFP4 4274/4885RXFP3 3328/4885INSR 4562/4885 |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | RXFP4 4601/4885RXFP3 3999/4885INSR 4297/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | RXFP4 2599/4885RXFP3 2342/4885INSR 4219/4885 |
| US-11267799-B2 | Solid forms of an HIV capsid inhibitor | ZC3HAV1, ZC3HAV1L, PRNP | RXFP4 4073/4885RXFP3 3365/4885INSR 4576/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | RXFP4 4683/4885RXFP3 4182/4885INSR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.